Information  X 
Enter a valid email address

Halma PLC (HLMA)


Tuesday 27 April, 2021

Halma PLC


RNS Number : 6459W
Halma PLC
27 April 2021

Halma plc ('Halma' or the 'Group')


Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today announces that it has acquired PeriGen, Inc., ("PeriGen"), based in North Carolina, USA.

PeriGen's advanced technology protects mothers and their unborn babies by alerting doctors, midwives and nurses to potential problems during childbirth. Its software solutions use artificial intelligence to provide an automated early warning platform during labour, enabling healthcare professionals to assess complex data more easily and allowing them to spend more time on direct patient care.

The cash consideration for PeriGen is US$58m (approximately £42m), on a cash and debt free basis, which will be funded from Halma's existing facilities. PeriGen's unaudited revenue for the 12 months to the end of March 2021 was approximately US$20m (approximately £14m), with return on sales slightly above Halma's target range of 18%-22%.

Andrew Williams, Group Chief Executive at Halma, commented:

"We are excited by the opportunities offered by PeriGen's digital technology in helping clinicians protect the health of mothers and babies during childbirth, while achieving better clinical outcomes in the increasing proportion of complex births. PeriGen is highly aligned with our purpose, broadens our presence in patient assessment and monitoring into the US perinatal care market, and further extends our artificial intelligence and analytics capabilities."

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive  +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations  +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs                                           +44 (0) 7384 796 013 

MHP Communications

Andrew Jaques / Giles Robinson +44 (0)20 3128 8788

A copy of this announcement, together with other information about Halma, may be viewed on its website:




About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2021, Halma was named Britain's Most Admired Company by Management Today.

Further information on PeriGen

PeriGen's Electronic Fetal Monitoring (EFM) software is used in childbirth to continuously assess fetal heart rate and contraction patterns, maternal vital signs, and labour progress at both the bedside and from central nursing stations. It provides clinical warning signs during labour, including trending alerts to notify clinicians of situations that may require interventions.

PeriGen's Vigilance early warning system is the only FDA cleared, automated and continuous assessment tool for trending maternal and fetal clinical warning signs in childbirth. This analytics solution is powered by an AI machine-learning algorithm that guides doctors and nurses during childbirth.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t